Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

• Drug: PF-04531083 or Placebo
  
  Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
• Drug: PF-04531083 or Placebo
  
  Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
• Drug: PF-04531083 or Placebo
  
  Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
• Drug: PF-04531083 or Placebo
  
  A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.

• Experimental: Cohort 1
  
  Intervention: Drug: PF-04531083 or Placebo
• Experimental: Cohort 2
  
  Intervention: Drug: PF-04531083 or Placebo
• Experimental: Cohort 3
  
  Intervention: Drug: PF-04531083 or Placebo
• Experimental: Cohort 4
  
  Intervention: Drug: PF-04531083 or Placebo

Inclusion Criteria:

• Healthy male and/or female subjects btween the ages of 18-55 years
• Body Mass Index (BMI) of 15.5 to 30.5 and a total body weight greater than 50kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically signifcant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
• A positive urine drug screen.
• History of regular alcohol consumption exceeding 21 drinks/week within 6 months of screening
• Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day.
• Pregnant or nursing females; females of childbearing potentioal who are unwilling or unable to use an acceptable method on contraception.